IFRX InflaRx N.V.

NASDAQ
$1.11

InflaRx N.V. (IFRX) is expected to report earnings on February 2, 2027, before the market open. The consensus earnings estimate is a loss of $0.05 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -33.5% since its last earnings release on November 3, 2026.

InflaRx N.V. Beat Consensus Estimates
Tuesday, November 3, 2026 · 12:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · Before Open
Earnings Whisper
-
vs ($0.05)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.41

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About InflaRx N.V.

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.